Enlivex Therapeutics Ltd ENLV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ENLV is a good fit for your portfolio.
News
-
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
-
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
-
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
-
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
-
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
-
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
Trading Information
- Previous Close Price
- $1.40
- Day Range
- $1.36–1.37
- 52-Week Range
- $1.15–4.59
- Bid/Ask
- $1.35 / $1.38
- Market Cap
- $25.48 Mil
- Volume/Avg
- 14,102 / 181,320
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 77
- Website
- https://www.enlivex.com
Valuation
|
Metric
|
ENLV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.67 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ENLV
|
|---|---|
Quick Ratio | 7.34 |
Current Ratio | 7.34 |
Interest Coverage | — |
Quick Ratio
ENLV
Profitability
|
Metric
|
ENLV
|
|---|---|
Return on Assets (Normalized) | −38.54% |
Return on Equity (Normalized) | −45.57% |
Return on Invested Capital (Normalized) | −41.68% |
Return on Assets
ENLV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jkhvbdwnyb | Hbgdk | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sqywqyvyj | Tfzcq | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ytndhpvv | Ymmwvyp | $98.1 Bil | |
MRNA
| Moderna Inc | Dznrlgfjf | Qhhsb | $39.1 Bil | |
ARGX
| argenx SE ADR | Pjqlpkjby | Hckx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Fxkhjmslw | Lqdf | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fzphygyj | Rwbwvy | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gskyjmbbk | Wdxbf | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvhrtlhqm | Kqhzng | $12.5 Bil | |
INCY
| Incyte Corp | Mqbrkphgf | Cnkjx | $11.9 Bil |